MCET (MultiCell Technologies) Effective Interest Rate on Debt %: 11.43% (As of Aug. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MultiCell Technologies Effective Interest Rate on Debt %?

MultiCell Technologies MCET -90.00% Effective Interest Rate on Debt % is 11.43% as of Aug. 2015.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. MultiCell Technologies's annualized positive value of Interest Expense for the quarter that ended in Aug. 2015 was $0.00 Mil. MultiCell Technologies's average total debt for the quarter that ended in Aug. 2015 was $0.04 Mil. Therefore, MultiCell Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Aug. 2015 was 11.43%.


MultiCell Technologies  (OTCPK:MCET) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


MultiCell Technologies Effective Interest Rate on Debt % Related Terms


MultiCell Technologies Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for MultiCell Technologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MultiCell Technologies Effective Interest Rate on Debt % Chart

MultiCell Technologies Annual Data
Trend Nov05 Nov06 Nov07 Nov08 Nov09 Nov10 Nov11 Nov12 Nov13 Nov14
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 71.07 43.24 13.79 5.94 27.16

MultiCell Technologies Quarterly Data
Nov10 Feb11 May11 Aug11 Nov11 Feb12 May12 Aug12 Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.39 10.81 11.11 11.27 11.43

MCET vs ERGO, OPLI, GLAG: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, MultiCell Technologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MultiCell Technologies Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MultiCell Technologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where MultiCell Technologies's Effective Interest Rate on Debt % falls into.



MultiCell Technologies Effective Interest Rate on Debt % Calculation

MultiCell Technologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Nov. 2014 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Nov. 2013 )+Total Debt  (A: Nov. 2014 ))/ count )
=-1  *  -0.011/( (0.045+0.036)/ 2 )
=-1  *  -0.011/0.0405
=27.16 %

where

MultiCell Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Aug. 2015 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: May. 2015 )+Total Debt  (Q: Aug. 2015 ))/ count )
=-1  *  -0.004/( (0.035+0.035)/ 2 )
=-1  *  -0.004/0.035
=11.43 %

where

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Aug. 2015) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 11.43% mean?
MultiCell Technologies (MCET) has a Effective Interest Rate on Debt % of 11.43% as of Aug. 2015. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on MultiCell Technologies and its competitors.
Is MultiCell Technologies' Effective Interest Rate on Debt % too high?
MultiCell Technologies' current Effective Interest Rate on Debt % is 11.43%.
How does MultiCell Technologies' Effective Interest Rate on Debt % compare to ERGO and OPLI?
MultiCell Technologies' Effective Interest Rate on Debt % of 11.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on MultiCell Technologies and its competitors. MultiCell Technologies's current Effective Interest Rate on Debt % is 11.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Effective Interest Rate on Debt % of 11.43%. The current Effective Interest Rate on Debt % is 11.43%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Effective Interest Rate on Debt % is 11.43% as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MultiCell Technologies Business Description

Address 4144 North Central Expressway, Suite 600, Dallas, TX, USA, 75204
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.